Cancer Science Conflict of Interest Policy

Transcription

1 Updated on 15 February 2018 Cancer Science Conflict of Interest Policy The Japanese Cancer Association (JCA) requires authors, editors and reviewers, to disclose any potential conflict of interest related to articles submitted for publication in Cancer Science. A conflict of interest exists when anyone has financial or personal relationships that could inappropriately influence (bias) his or her actions. The intent of the JCA Conflict of Interest disclosure policy is to provide authors, editors, and readers with all the facts necessary to make informed judgments about the content of Cancer Science. will be required to complete a conflict of interest disclosure form as part of the initial manuscript submission process. The corresponding author is responsible for obtaining accurate information of conflict of interest forms from all authors of the manuscript. The disclosure of a potential conflict of interest does not necessarily affect the manuscript s chances of acceptance. Disclosures, only when clearly related to the topic of the present manuscript, will appear as Disclosure Statement in the published article. Disclosures that the author deems relevant will be disclosed publicly. Serious failure by any author to disclose a conflict that later comes to light will result in a ban on the author publishing in Cancer Science for a maximum of 3 years. Editors and Associate Editors are required to fill out conflict of interest disclosure forms on an annual basis. Editors, Associate Editors and persons asked to peer review a manuscript, should voluntarily remove themselves from involvement in any manuscript review or discussion if they believe they could have a conflict of interest.

2 Cancer Science : Conflict of Interest Disclosure Updated on 15 February 2018 WEB Manuscript title Author s name AUTHORS: Complete this form ONLY as it relates to the manuscript you are currently submitting. Cite by company name or other description, all commercial and/or financial relationships within the past 3 years that may be relevant to the topic of the manuscript and might be perceived as a real or potential conflict of interest. Relevant means that the relationship involves the same or similar subject matter; the same, similar or competing drug or device, product or service, intellectual property or asset; or has the potential to result in financial, professional or other personal gain or loss for you or an immediate family member (spouse, family related in the first degree, or people who share income/property with you). IF THERE IS NO RELATIONSHIP RELEVANT TO THE MANUSCRIPT S SUBJECT, INDICATE NONE IN THE APPROPRIATE CATEGORIES ON THE CHART (NEXT PAGE).

3 Conflict of Interest Disclosure Form Updated on 15 February 2018 WEB Categories No Yes (Give names of authors, their spouse, family related in the first degree, or people who share income/property with them and entities) 1. Annual value of remuneration received from a single company or for-profit organization as an officer or an advisor (including consultant, etc.) is 1 million yen/us$10,000 or more 2. Annual profit from shares (or latent profit from stock options) of a single company is 1 million yen/us$10,000 or more or the proportion of shares owned in the company is 5% or more 3. Annual profit (the sum of royalties, licensing fees, and the gain from transfer of patent right(s)) for a single patent is 1 million yen/us$10,000 or more in total 4. Total annual value of daily allowances/honoraria (lecture fees or fees for the chairperson or the moderator) received from a single company or for-profit organization as compensation for the time or labor of a researcher retained for conference attendance (for a presentation or serving as the chairperson or the moderator, etc.) is 500,000 yen/us$5,000 or more 5. Total annual value of manuscript fees received from a single company or for-profit organization is 500,000 yen/us$5,000 or more

4 Categories No Updated on 15 February 2018 Yes (Give names of authors, their spouse, family related in the first degree, or people who share income/property with them and entities) 6. Total annual value of research funds (collaborative research funds, contract research funds, clinical trial funds, private funders research grants, etc.), endowments, endowed chairs, and researcher-employment costs received organization is 1 million yen/us$10,000 or more * With regard to scholarship endowments, state those cases where the individual declarer, the department of affiliation of the declarer or the representative of that department was paid. *With regard to endowed chairs, this means cases where the declarers are affiliated with the endowed chair that the Company, etc. provides. 7. Other annual remuneration received organization (travel expenses, gifts, etc., that are not directly related to research) is 50,000 yen/us$500 or more Please attach any additional details as necessary. On behalf of all authors of this manuscript, I confirm that the information reported above is accurate. I understand that this information will be disclosed publicly. The JCA reserves the right to decline to publish our work if the Association believes a serious conflict of interest exists. I understand that failure to complete this form will disqualify our manuscript from consideration for publication. Serious Failure by any author to disclose a conflict that later comes to light will result in a ban on the corresponding author publishing in Cancer Science for a period of maximum 3 years. Corresponding Author s Name Signature Date

5 Example Conflict of Interest Disclosure Form WEB Categories No Yes (Give names of authors, their spouse, family related in the first degree, or people who share income/property with them and entities) 1. Annual value of remuneration received from a single company or for-profit organization as an officer or an advisor (including consultant, etc.) is 1 million yen/us$10,000 or more Thomas Edison from XXXX corporation Isaac Newton from YYY corporation 2. Annual profit from shares (or latent profit from stock options) of a single company is 1 million yen/us$10,000 or more or the proportion of shares owned in the company is 5% or more Charles Edison from YYY, Inc (Child of Thomas Edison) 3. Annual profit (the sum of royalties, licensing fees, and the gain from transfer of patent right(s)) for a single patent is 1 million yen/us$10,000 or more in total 4. Total annual value of daily allowances/honoraria (lecture fees or fees for the chairperson or the moderator) received from a single company or for-profit organization as compensation for the time or labor of a researcher retained for conference attendance (for a presentation or serving as the chairperson or the moderator, etc.) is 500,000 yen/us$5,000 or more 5. Total annual value of manuscript fees received from a single company or for-profit organization is 500,000 yen/us$5,000 or more

6 Example Categories 6. Total annual value of research funds (collaborative research funds, contract research funds, clinical trial funds, private funders research grants, etc.), endowments, endowed chairs, and researcher-employment costs received organization is 1 million yen/us$10,000 or more * With regard to scholarship endowments, state those cases where the individual declarer, the department of affiliation of the declarer or the representative of that department was paid. *With regard to endowed chairs, this means cases where the declarers are affiliated with the endowed chair that the Company, etc. provides. 7. Other annual remuneration received Yes (Give names of authors, their spouse, family related in No the first degree, or people who share income/property with them and entities) Thomas Edison from ZZZ corporation organization (travel expenses, gifts, etc., that are not directly related to research) is 50,000 yen/us$500 or more Nancy Newton from WWW corporation (Wife of Isaac Newton) Please attach any additional details as necessary. On behalf of all authors of this manuscript, I confirm that the information reported above is accurate. I understand that this information will be disclosed publicly. The JCA reserves the right to decline to publish our work if the Association believes a serious conflict of interest exists. I understand that failure to complete this form will disqualify our manuscript from consideration for publication. Serious Failure by any author to disclose a conflict that later comes to light will result in a ban on the corresponding author publishing in Cancer Science for a period of maximum 3 years. Corresponding Author s Name Thomas Edison Signature Date